Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Acquisitions & Divestments: 2015-2024

Historic Change in Acquisitions & Divestments for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to $42.6 million.

  • Corvus Pharmaceuticals' Change in Acquisitions & Divestments rose 90.89% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year increase of 97.73%. This contributed to the annual value of $42.6 million for FY2024, which is 31.93% down from last year.
  • As of FY2024, Corvus Pharmaceuticals' Change in Acquisitions & Divestments stood at $42.6 million, which was down 31.93% from $62.6 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $86.4 million during FY2020, and its lowest value of $30.9 million during FY2021.
  • For the 3-year period, Corvus Pharmaceuticals' Change in Acquisitions & Divestments averaged around $49.5 million, with its median value being $43.2 million (2022).
  • Per our database at Business Quant, Corvus Pharmaceuticals' Change in Acquisitions & Divestments slumped by 64.20% in 2021 and then spiked by 45.09% in 2023.
  • Corvus Pharmaceuticals' Change in Acquisitions & Divestments (Yearly) stood at $86.4 million in 2020, then crashed by 64.20% to $30.9 million in 2021, then spiked by 39.58% to $43.2 million in 2022, then surged by 45.09% to $62.6 million in 2023, then slumped by 31.93% to $42.6 million in 2024.